---
title: "Amanta Healthcare Ltd (AMANTA) — Share Price, Financials & Analysis"
symbol: "AMANTA"
company: "Amanta Healthcare Ltd"
canonical: "https://tapetide.com/stocks/AMANTA"
isin: "INE084K01015"
nse_symbol: "AMANTA"
bse_code: "544502"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 783.5
generated_at: "2026-09-13T18:46:35.182Z"
---

# Amanta Healthcare Ltd (AMANTA)

Canonical page: https://tapetide.com/stocks/AMANTA

## Company

- **NSE Symbol:** AMANTA
- **BSE Code:** 544502
- **ISIN:** INE084K01015
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-09-09
- **CEO:** Mr. Bhavesh Girishbhai Patel
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** amanta.co.in

## About

Incorporated in December 1994, Amanta Healthcare Limited is a pharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse array of sterile liquid products.[1]

## Latest Price

- **Price:** ₹197.75
- **Change:** -4.03 (-2%)
- **Open:** ₹197.75
- **Day High:** ₹197.75
- **Day Low:** ₹197.75
- **Previous Close:** ₹201.78
- **Volume:** 19137
- **As Of:** 2026-09-11T09:45:06+00:00

## Key Fundamentals

Observed at 2026-09-11T04:51:15.777108Z.

- **Market Cap:** ₹783.5 Cr
- **Classification:** Microcap
- **P/E (reported):** 53.6
- **P/E (TTM):** 52.45
- **EPS (TTM):** ₹3.77
- **Book Value:** ₹56.71
- **Price to Book:** 3.57
- **Dividend Yield:** 0%
- **ROE:** 6.75%
- **ROCE:** 10.04%
- **Debt to Equity:** 1.11
- **Revenue (yearly):** ₹291 Cr
- **Net Income:** ₹14.9 Cr
- **EBITDA:** ₹63.2 Cr
- **52-Week High:** ₹209.95
- **52-Week Low:** ₹92
- **RSI (14):** 64.36

## Tapetide Score

- **Score:** 39 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 12 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 17.89 | 9% |
| growth | 26.66 | 9% |
| momentum | 92.61 | 12% |
| ownership | 38.86 | 24% |
| quality | 46.4 | 22% |
| valuation | 35.82 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has delivered good profit growth of 22.4% CAGR over last 5 years

### Weaknesses

- Stock is trading at 3.49 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 10.9% over past five years.
- Company has a low return on equity of 10.0% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 3.93% | -16.57% | -21.65% |
| ebitda margin growth | -8.43% | -1.76% | 4.12% | -7.85% |
| net income growth | -40% | 41.9% | 114% | 22% |
| revenue growth | -11.82% | 5.4% | 4% | 11% |
| roce | — | -37.21% | -35.56% | 18.81% |
| roe | — | -38.02% | 7.71% | -91.13% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 68.1 | 66.73 | 67.81 | 72.06 | 65.31 | 70.89 | 74.49 | 76.99 | 68.8 |
| Expenses | 54.7 | 52.85 | 52.75 | 53.1 | 50.41 | 56.24 | 59.13 | 62.03 | 54.26 |
| Operating Profit | 13.4 | 13.88 | 15.06 | 18.96 | 14.9 | 14.65 | 15.36 | 14.96 | 14.54 |
| OPM % | 19.68 | 20.8 | 22.21 | 26.31 | 22.81 | 20.67 | 20.62 | 19.43 | 21.13 |
| Other Income | 0.15 | 0.21 | 0.87 | 0.16 | 0.96 | -2.56 | 0.68 | 1.66 | 0.64 |
| Interest | 9.45 | 6.32 | 5.9 | 6.28 | 6.29 | 5.15 | 5.06 | 4.25 | 6 |
| Depreciation | 4.6 | 4.6 | 4.51 | 4.69 | 4.64 | 4.66 | 4.67 | 4.75 | 4.69 |
| Profit before tax | -0.5 | 3.17 | 5.52 | 8.15 | 4.93 | 2.28 | 6.31 | 7.62 | 4.49 |
| Tax % | -28 | 28.71 | 22.64 | 26.87 | 28.8 | 46.93 | 26.47 | 27.43 | 26.28 |
| Net Profit | -0.36 | 2.26 | 4.28 | 5.96 | 3.51 | 1.21 | 4.63 | 5.53 | 3.31 |
| EPS in Rs | -0.13 | 0.78 | 1.48 | 2.07 | 1.22 | 0.31 | 1.19 | 1.42 | 0.85 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 184 | 171 | 225 | 259 | 280 | 275 | 288 | 291 |
| Expenses | 147 | 133 | 173 | 206 | 223 | 215 | 228 | 232 |
| Operating Profit | 37 | 38 | 52 | 53 | 58 | 60 | 60 | 60 |
| OPM % | 20 | 22 | 23 | 20 | 21 | 22 | 21 | 20 |
| Other Income | 2 | 1 | 76 | 4 | 1 | 1 | 1 | 0 |
| Interest | 38 | 40 | 49 | 35 | 34 | 28 | 21 | 20 |
| Depreciation | 16 | 17 | 17 | 18 | 20 | 18 | 19 | 19 |
| Profit before tax | -15 | -18 | 62 | 3 | 5 | 15 | 21 | 21 |
| Tax % | 25 | 23 | 11 | 179 | 32 | 29 | 30 | — |
| Net Profit | -19 | -22 | 55 | -2 | 4 | 10 | 15 | 15 |
| EPS in Rs | -7.03 | -8.14 | 20.54 | -0.79 | 1.35 | 3.64 | 3.83 | 3.77 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 27 | 27 | 27 | 27 | 27 | 29 | 39 |
| Reserves | 2 | -20 | 36 | 36 | 39 | 68 | 181 |
| Borrowings | 231 | 235 | 226 | 216 | 211 | 204 | 244 |
| Other Liabilities | 127 | 150 | 104 | 96 | 75 | 81 | 93 |
| Total Liabilities | 388 | 392 | 392 | 374 | 352 | 382 | 558 |
| Fixed Assets | 244 | 242 | 240 | 232 | 228 | 217 | 207 |
| CWIP | 0 | 0 | 0 | 9 | 0 | 7 | 82 |
| Investments | 0 | 2 | 3 | 0 | 4 | 8 | 7 |
| Other Assets | 144 | 149 | 149 | 133 | 120 | 150 | 262 |
| Total Assets | 388 | 392 | 392 | 374 | 352 | 382 | 558 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 38 | 31 | 62 | 43 | 58 | 47 | 48 |
| Cash from Investing Activity | -9 | -13 | -6 | -7 | -10 | -24 | -94 |
| Cash from Financing Activity | -37 | -18 | -50 | -42 | -46 | -23 | 126 |
| Net Cash Flow | -8 | 0 | 6 | -6 | 1 | -1 | 81 |
| Free Cash Flow | 27 | 19 | 52 | 36 | 46 | 26 | -32 |
| CFO/OP | 102 | 66 | 119 | 93 | 111 | 84 | 93 |

### Ratios

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 104 | 110 | 73 | 75 | 63 | 67 | 55 |
| Inventory Days | 225 | 422 | 338 | 247 | 309 | 464 | 530 |
| Days Payable | 99 | 186 | 185 | 130 | 129 | 194 | 230 |
| Cash Conversion Cycle | 229 | 345 | 226 | 193 | 243 | 336 | 354 |
| Working Capital Days | 51 | -5 | 28 | 42 | 16 | 26 | 6 |
| ROCE % | — | 9 | 14 | 13 | 14 | 15 | 12 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2024 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Promoters | 85.52% | 63.56% | 63.56% | 63.56% | 63.72% | 63.8% |
| FIIs | 0% | 2.21% | 1% | 1.1% | 0.85% | 0.43% |
| DIIs | 0% | 12.22% | 11.34% | 11.24% | 12.88% | 12.92% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 0% | 20.28% | 17.35% | 16.91% | 16% | 17.45% |
| Others | 14.48% | 1.74% | 6.75% | 7.19% | 6.56% | 5.39% |
| No. of Shareholders | 192 | 30695 | 360 | 16181 | 15222 | 12612 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 6 / 0

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 195.47 | Buy |
| EMA (10) | 196.32 | Buy |
| SMA (20) | 190.73 | Buy |
| EMA (20) | 190.18 | Buy |
| SMA (50) | 176.93 | Buy |
| EMA (50) | 177.04 | Buy |
| SMA (100) | 158.41 | Buy |
| EMA (100) | 161.81 | Buy |
| SMA (200) | 132.16 | Buy |
| EMA (200) | 143.38 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 60.03 | Neutral |
| MACD (12,26,9) | 7.95 | Buy |
| Stochastic (14,3,3) | 74.36 | Neutral |
| ADX (14) | 29.05 | Buy |
| Williams %R (14) | -46.07 | Neutral |
| ATR (14) | 5.4 | Neutral |
| ROC (12) | 3.52 | Buy |
| Stoch RSI (14) | 24.46 | Neutral |
| UO (7,14,28) | 56.08 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-03 | [Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ede1b249-cc62-4a2f-be70-da3a56c79a01.pdf) |
| 2026-09-02 | [Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Amanta Healthcare Limited Announces Commissioning Of New Steriport Line](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=08864405-b315-4338-ac72-318887d7e887.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ddb90dc6-2b0f-453e-ad3a-5c1ec2843555.pdf) |
| 2026-08-25 | [Intimation - Regulation 36(1)(B) Of The SEBI Listing Regulations](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=761c6c15-edfa-458e-85d8-c5f37052bfd5.pdf) |
| 2026-08-24 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f6dc7e2-1410-46e0-a5e3-78e52df607f3.pdf) |
| 2026-08-24 | [Notice Of 31St Annual General Meeting And Annual Report For F.Y. 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=21693c8c-d04b-4cd1-8f68-d44033771690.pdf) |
| 2026-08-24 | [Annual Report For Financial Year 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=31894ba1-3f48-4c00-95da-b0c9ffac167b.pdf) |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bd5005d3-1281-4e87-a338-cb0c23ff80a4.pdf) |
| 2026-08-08 | [Announcement under Regulation 30 (LODR)-Monitoring Agency Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0464a1c9-3f5f-4ce9-bd3c-a709248b7360.pdf) |
| 2026-08-07 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bdb0a6c9-18c3-47b0-9cc6-70097575dc17.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-08 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2afbb05e-bda5-470b-adc9-05b75b13367a.pdf) |
| 2026-05-21 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0b4a3e89-e3b2-477f-ab43-10c479683654.pdf) |
| 2026-02-16 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=99160f22-d1c9-4617-b2c9-e8f17bfc65f3.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-06 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=67127ef5-ffd1-4126-9516-8fb0965382e9.pdf) |
| 2026-05-19 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c001c9c0-f314-409d-8a22-3fb3583742e1.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-05 | [To Approve Unaudited Financial Results For The Quarter Ended 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ea1dc6a2-0590-41bc-9d87-7ba06b9dc7f8.pdf) |
| 2026-05-19 | [Financial Results For FY 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2482f14e-6549-412a-94ee-0f2b257eb95c.pdf) |
| 2026-02-10 | [Unaudited Financial Results For Q3 Of FY 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=821df963-f7dc-44e3-94c9-cd1a573a20b4.pdf) |
| 2025-11-13 | [Re Submission Of Financial Results For Quarter And Half Year Ended September 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=436a9fad-90f5-484b-b229-2e2395a0ae7f.pdf) |
| 2025-11-11 | [To Approve Unaudited Financial Results For Q2 Of FY 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=90cd720a-7148-4211-a47b-09da8fe6efcf.pdf) |
| 2025-09-26 | [Result - Financial Results For Q1 Of 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9af82d85-9404-4ef1-b5f4-49ceda83b92d.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c4e3a165-7304-495c-a9ee-34ac7d6c2596.pdf) |
| 2026-02-11 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=56071f05-5b99-495e-9663-52c5af368ba1.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Apr - Amanta Healthcare held a group analyst/institutional investor site visit on 7 April 2026. | [Analysts/Institutional Investor Meet/Outcome 9 Apr - Amanta Healthcare held a group analyst/institutional investor site visit on 7 April 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3fd8bc96-b484-4c0a-b90f-598e85045f36.pdf) |
| 8 Apr - Amanta Healthcare Limited has informed about certificate under SEBI (Depositories and Participants) Regulations, 2018 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr - Amanta Healthcare Limited has informed about certificate under SEBI (Depositories and Participants) Regulations, 2018](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d1a43444-cef8-4a39-bc66-aa6bdc2ccac1.pdf) |
| 31 Jan - Copy of Newspaper Publication for the quarter and nine months ended 31st December,2025 | [Announcement under Regulation 30 (LODR)-Newspaper Publication 31 Jan - Copy of Newspaper Publication for the quarter and nine months ended 31st December,2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8bb2b49d-1827-459b-823f-a0119204c495.pdf) |
| 28 Mar - Trading window closed April 1, 2026 until 48 hours after FY2026 audited results submission. | [Closure of Trading Window 28 Mar - Trading window closed April 1, 2026 until 48 hours after FY2026 audited results submission.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/78297314-0022-4572-a254-d5881e078ef3.pdf) |
| 27 Feb - Promoter Bhavesh Patel bought 48,151 shares in open market on Feb 26-27, 2026; Form C filed. | [Open Market Purchase Of Equity Shares By Promoter 27 Feb - Promoter Bhavesh Patel bought 48,151 shares in open market on Feb 26-27, 2026; Form C filed.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8d77b547-ce93-484a-99dd-e49c4906ad6f.pdf) |
| 22 Apr - Promoter Bhavesh Patel’s 15,500 shares credited on April 17, 2026; holding rose to 16.29%. | [Clarification Letter On Earlier Disclosure Submitted On April 18Th, 2026, Pursuant To SEBI (PIT) Regulations, 2015 22 Apr - Promoter Bhavesh Patel’s 15,500 shares credited on April 17, 2026; holding rose to 16.29%.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/af349cc9-f4ea-4697-96a8-02bedd3b1fb5.pdf) |
| 2 Feb - Audio recording of Feb 2, 2026 investor call on Q3 and nine-month unaudited results (ended Dec 31, 2025) uploaded. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 2 Feb - Audio recording of Feb 2, 2026 investor call on Q3 and nine-month unaudited results (ended Dec 31, 2025) uploaded.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2c7f1f24-2564-4c67-a425-2235747de174.pdf) |
| 2 Apr - Promoter disclosed no share encumbrance during FY 2025-26 under SEBI SAST Regulation 31(4). | [Disclosures Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011 2 Apr - Promoter disclosed no share encumbrance during FY 2025-26 under SEBI SAST Regulation 31(4).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ff3d1cb7-0ed7-4524-a6c3-99014a641abe.pdf) |
| 2 Apr - Analysts/institutional investors group site visit scheduled on 7 April 2026 in Kheda, Gujarat. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2 Apr - Analysts/institutional investors group site visit scheduled on 7 April 2026 in Kheda, Gujarat.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b11ca968-8e27-4ea5-a4bc-f3cb5f9d9d62.pdf) |
| 18 Apr - Promoter Bhavesh Patel actually received 13,300 shares, not 28,800; earlier disclosure revised. | [Clarification On Earlier Disclosure Submitted On April 1St, 2026 18 Apr - Promoter Bhavesh Patel actually received 13,300 shares, not 28,800; earlier disclosure revised.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c8754533-9219-4aba-9227-c1ffffe36358.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/55c10fc2-55ae-4542-93b0-74df96ff76fc.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0b4a3e89-e3b2-477f-ab43-10c479683654.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/0b4a3e89-e3b2-477f-ab43-10c479683654.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/c7f43b49-6d75-4746-8a10-21814b013d45.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d1cff658-c28c-4a14-ab0d-286aaca90a68.pdf) |
| May 2019 | [Concall - May 2019](https://www.bseindia.com/xml-data/corpfiling/AttachHis/51b13c3a-25c6-4c94-9b20-8be6ff2f05cf.pdf) |
| May 2017 | [Concall - May 2017](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/5/d05d6d33-f7ce-4627-a213-73e41c595bd6.pdf) |
| Jan 2026 | [Concall - Jan 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fb16467e-d240-49bb-8f16-9529d5f51104.pdf) |
| Jan 2024 | [Concall - Jan 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/166a6f35-0bee-4894-a872-ac55f3865ea9.pdf) |
| Aug 2024 | [Concall - Aug 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4f23067c-ecd3-4037-a162-15366bcc8b50.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2011 from nse](https://archives.nseindia.com/annual_reports/AR_SUBROS_2010_2011_12092011043031.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5569ecf9-0df5-489a-8e94-bc3e15f20dd4.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c5b39d32-9b26-4998-af9f-2f1643dbab55.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7699eea5-67b3-43d8-9008-d43d3cbf4cc8.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/517168/73718517168.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/517168/69592517168.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/517168/64902517168.pdf) |
| from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/517168/5171680319.pdf) |
| from bse | [Financial Year 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/517168/5171680318.pdf) |
| from bse | [Financial Year 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/517168/5171680317.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:46:35.182Z.